EADV Congress

Dermatology is the cradle of manifold medical innovations

A number of innovative research results were presented at the 24th Congress of the European Academy of Dermatology and Venereology that took place in Copenhagen from 7 to 11 October 2015. Some of these results are expected to impact medicine far beyond dermatology, demonstrating the innovative character of the specialty.

Photo: Dermatology is the cradle of manifold medical innovations

The importance of the specialty becomes also obvious against the background of this year’s Nobel Prizes: William C. Campbell and Satoshi Ōmura were honoured for having addressed the importance of skin in infectious diseases, Tomas Lindahl, Paul Modrich and Aziz Sancar were awarded for their research into the mechanisms that cells use to repair DNA, which is vital for the understanding of skin cancer pathogenesis and skin ageing.

Research in psoriasis has led to new treatment options for inflammatory bowel diseases, rheumatoid arthritis and multiple sclerosis

The identification of disease pathways in psoriasis and the development of new targeted drugs (e.g. inhibitors of IL-17 and IL-23) has helped to understand the origin of inflammatory bowel diseases, rheumatoid arthritis and multiple sclerosis. Furthermore, treatments originally developed for psoriasis are now investigated in these diseases, and may be implemented in their standard therapy. A small molecule (fumarates), for example, has now been approved for the treatment of multiple sclerosis.

Insights into how skin cancer suppresses immunity will also lead to novel treatment options for other cancers

The first broadly efficient cancer immunotherapy has been developed in dermatology as a treatment for metastatic melanoma. The anti-PD-1 therapy can hold the progression of metastatic disease for more than 18 months as a new study has shown [1]. As Prof. Martin Röcken, MD, Tübingen, Germany, EADV Scientific Programming Committee Chairman, explained, the therapy will also be tested as treatment for other malignancies – and chances are good that patients with lung cancer, bladder or kidney cancer might benefit from it. But Röcken also pointed to the downside of this innovation. As with many new cancer drugs, treatment costs can add up to 250,000 EUR per patient, a sum, most health systems have difficulty to afford. This is especially worrisome, because the basic research for these therapies was performed in publicly-funded research institutes. ʺWe have to make sure that innovations reach the patients and we have to care that promising treatments do not become too expensive. This is a challenge medical doctors face nowadaysʺ, explains Röcken.

[1] Robert C et al. N Engl J Med. 2015 Jan 22;372(4):320-30

Source: EADV


Read all latest stories

Related articles



An 'on-off switch' for gene editing

Over the past decade, the CRISPR-Cas9 gene editing system has revolutionized genetic engineering, allowing scientists to make targeted changes to organisms’ DNA. While the system could potentially…


Mitochondria research

Colorectal cancer: Mutations in overlooked DNA could have huge impact on survival

DNA errors in the cell’s energy ‘factories’ increases the chances of survival for people with bowel cancer, also known as colorectal cancer, according to a new study. Studying how DNA errors…



Potential trigger of Crohn’s disease found

Potentially game-changing research led by McMaster University scientists may finally bring relief to millions of people worldwide living with Crohn’s disease. Investigator Brian Coombes said his…

Related products

Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

Fujifilm Wako – Hyaluronic Acid LT Assay

Clinical Chemistry

Fujifilm Wako – Hyaluronic Acid LT Assay

FUJIFILM Wako Chemicals Europe GmbH
Gene Science – Saliva Collection Kit

Gene Science – Saliva Collection Kit

Zhejiang Gene Science Co., Ltd.
Orion Diagnostica Oy – Orion GenRead


Orion Diagnostica Oy – Orion GenRead

Orion Diagnostics Oy
Subscribe to Newsletter